Butterfly Medical

Implantable Device for Nonsurgical BPH Treatment

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in October 2014 by Yehuda Bachar and Adrian Paz, Butterfly Medical operates with 11–50 employees. The company has raised $30M across 3 funding rounds from 7 investors. In May 2026, Butterfly Medical secured $21M in an upsized Series C funding round.

Business overview

Butterfly Medical is a Health Tech & Life Sciences company focused on developing a non-surgical treatment for benign prostatic hyperplasia (BPH). Its core product is the Butterfly implant, designed to fit the prostatic urethra, dilate the obstructed area, and restore urine flow. The company serves the healthcare market, specifically patients suffering from BPH, and operates within the Medical Devices and Medical Treatment & Therapeutics sectors.

Strategic signal

In May 2026, Butterfly Medical announced a $21M upsized Series C funding round to advance its minimally invasive BPH treatment. This significant capital injection validates investor confidence in the company's technology and its potential to address a widespread medical condition, signaling accelerated development and market penetration for its implantable device.

Company Intelligence Q&A

What was the most recent funding event for Butterfly Medical?
In May 2026, Butterfly Medical secured $21M in an upsized Series C funding round. New Rhein Healthcare Investors participated as a follow-on investor, alongside the European Innovation Council.
When did Butterfly Medical complete its pivotal trial for BPH treatment?
In January 2026, Butterfly Medical announced the successful completion of its pivotal trial for the minimally invasive treatment of benign prostatic hyperplasia (BPH).
Did Butterfly Medical receive CE Mark certification for its prostate device?
Yes, in November 2017, Butterfly Medical was awarded CE Mark certification for its prostate device, indicating compliance with European health, safety, and environmental protection standards.
When did Butterfly Medical last raise a Series B funding round?
In October 2020, Butterfly Medical raised a Series B funding round. New Rhein Healthcare Investors led this round, with Mori Arkin also participating as a follow-on investor.
What was the focus of the data presented at AUA 2025 by Butterfly Medical?
In April 2025, Butterfly Medical presented new data at AUA 2025 highlighting the effectiveness of its minimally invasive device for benign prostatic hyperplasia (BPH) treatment.

External links